Zydus wins USFDA approval for hormone patch with 180-day exclusivity

Zydus wins USFDA approval for hormone patch with 180-day exclusivity — Zydus Lifesciences has received USFDA approval for its Estradiol and Levonorgestrel Transdermal System, a hormone replacement therapy. The product is eligible for 180-day competitive generic therapy (CGT) exclusivity, offering a market edge. This approval expands Zydus’s presence in the U.S. generics segment and could boost near-term revenues.

📊 STOCKS: $ZYDUSLIFE | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #USFDA